https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-04-01 / Hum. Gene Ther. 2005 Apr;16(4):435-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-04-01 / Hum. Gene Ther. 2005 Apr;16(4):435-442005-04-01 00:00:002005-04-01 00:00:00Targeting vaccinia to solid tumors with local hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-31 / Vaccine 2005 Mar;23(19):2439-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-31 / Vaccine 2005 Mar;23(19):2439-532005-03-31 00:00:002020-06-23 09:38:03T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-28 / World J. Gastroenterol. 2005 Mar;11(12):1806-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-28 / World J. Gastroenterol. 2005 Mar;11(12):1806-82005-03-28 00:00:002019-02-15 08:37:47Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-732005-03-18 00:00:002019-02-15 09:19:58Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-772005-03-11 00:00:002019-02-15 08:50:35Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-01 / Lung Cancer 2005 Mar;47(3):337-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-01 / Lung Cancer 2005 Mar;47(3):337-502005-03-01 00:00:002019-02-15 08:45:37The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-01 / J. Virol. 2005 Mar;79(5):3052-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-01 / J. Virol. 2005 Mar;79(5):3052-622005-03-01 00:00:002019-02-15 09:15:20Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-3032005-03-01 00:00:002020-06-23 09:38:35Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-02-15 / Cancer 2005 Feb;103(4):763-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-02-15 / Cancer 2005 Feb;103(4):763-712005-02-15 00:00:002019-02-15 08:35:13A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-02-01 / HBPD INT 2005 Feb;4(1):121-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-02-01 / HBPD INT 2005 Feb;4(1):121-52005-02-01 00:00:002019-02-15 08:36:23Effects of dendritic cells transfected with full length wild-type p53 and modified by bile duct cancer lysates on immune response
